Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in posimenopausal women

C. Boschetti, M. Cortellaro, T. Nencioni, V. Bertolli, A. Della Volpe, C. Zanussi

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

We compared the effects on hemostatic variables of transdermal estradiol and oral equine conjugated estrogens (CEE), both combined with medroxyprogesterone acetate, in 40 postmenopausal women, 22 randomly allocated to transdermal estradiol and 18 to CEE. Antithrombin III (AtIII), fibrinogen, factor VII, factor VIII and tissue plasminogen activator before and after venous stasis were measured at the start of therapy and after two and four months in all patients, and after 12 months in a subgroup of 21 patients (12 from the estradiol and nine from the CEE group). In the short-term study (two and four months), analysis of variance did not reveal any significant difference between treatments for any of the hemostatic variables. A significant treatment by time interaction was found only for fibrinogen levels: at two months they were significantly higher in the estradiol group. In the long-term study (12 months), a significant decrease in AtIII and a significant increase in factor VIII were observed in both groups, without differences between treatments. The clinical relevance of the observed changes is doubtful, but nevertheless they should be considered in a more extensive evaluation of the potential cardiovascular risk and benefits of hormone use.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalThrombosis Research
Volume62
Issue number1-2
DOIs
Publication statusPublished - 1991

Fingerprint

Conjugated (USP) Estrogens
Medroxyprogesterone Acetate
Blood Coagulation Factors
Hormone Replacement Therapy
Estradiol
Antithrombin III
Factor VIII
Hemostatics
Fibrinogen
Factor VII
Tissue Plasminogen Activator
Therapeutics
Analysis of Variance
Hormones

Keywords

  • Antithrombin III
  • factor VIII
  • thromboembolic risk

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology

Cite this

Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in posimenopausal women. / Boschetti, C.; Cortellaro, M.; Nencioni, T.; Bertolli, V.; Della Volpe, A.; Zanussi, C.

In: Thrombosis Research, Vol. 62, No. 1-2, 1991, p. 1-8.

Research output: Contribution to journalArticle

@article{d9b570fa74454746aeaba280ecddce91,
title = "Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in posimenopausal women",
abstract = "We compared the effects on hemostatic variables of transdermal estradiol and oral equine conjugated estrogens (CEE), both combined with medroxyprogesterone acetate, in 40 postmenopausal women, 22 randomly allocated to transdermal estradiol and 18 to CEE. Antithrombin III (AtIII), fibrinogen, factor VII, factor VIII and tissue plasminogen activator before and after venous stasis were measured at the start of therapy and after two and four months in all patients, and after 12 months in a subgroup of 21 patients (12 from the estradiol and nine from the CEE group). In the short-term study (two and four months), analysis of variance did not reveal any significant difference between treatments for any of the hemostatic variables. A significant treatment by time interaction was found only for fibrinogen levels: at two months they were significantly higher in the estradiol group. In the long-term study (12 months), a significant decrease in AtIII and a significant increase in factor VIII were observed in both groups, without differences between treatments. The clinical relevance of the observed changes is doubtful, but nevertheless they should be considered in a more extensive evaluation of the potential cardiovascular risk and benefits of hormone use.",
keywords = "Antithrombin III, factor VIII, thromboembolic risk",
author = "C. Boschetti and M. Cortellaro and T. Nencioni and V. Bertolli and {Della Volpe}, A. and C. Zanussi",
year = "1991",
doi = "10.1016/0049-3848(91)90663-H",
language = "English",
volume = "62",
pages = "1--8",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "1-2",

}

TY - JOUR

T1 - Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in posimenopausal women

AU - Boschetti, C.

AU - Cortellaro, M.

AU - Nencioni, T.

AU - Bertolli, V.

AU - Della Volpe, A.

AU - Zanussi, C.

PY - 1991

Y1 - 1991

N2 - We compared the effects on hemostatic variables of transdermal estradiol and oral equine conjugated estrogens (CEE), both combined with medroxyprogesterone acetate, in 40 postmenopausal women, 22 randomly allocated to transdermal estradiol and 18 to CEE. Antithrombin III (AtIII), fibrinogen, factor VII, factor VIII and tissue plasminogen activator before and after venous stasis were measured at the start of therapy and after two and four months in all patients, and after 12 months in a subgroup of 21 patients (12 from the estradiol and nine from the CEE group). In the short-term study (two and four months), analysis of variance did not reveal any significant difference between treatments for any of the hemostatic variables. A significant treatment by time interaction was found only for fibrinogen levels: at two months they were significantly higher in the estradiol group. In the long-term study (12 months), a significant decrease in AtIII and a significant increase in factor VIII were observed in both groups, without differences between treatments. The clinical relevance of the observed changes is doubtful, but nevertheless they should be considered in a more extensive evaluation of the potential cardiovascular risk and benefits of hormone use.

AB - We compared the effects on hemostatic variables of transdermal estradiol and oral equine conjugated estrogens (CEE), both combined with medroxyprogesterone acetate, in 40 postmenopausal women, 22 randomly allocated to transdermal estradiol and 18 to CEE. Antithrombin III (AtIII), fibrinogen, factor VII, factor VIII and tissue plasminogen activator before and after venous stasis were measured at the start of therapy and after two and four months in all patients, and after 12 months in a subgroup of 21 patients (12 from the estradiol and nine from the CEE group). In the short-term study (two and four months), analysis of variance did not reveal any significant difference between treatments for any of the hemostatic variables. A significant treatment by time interaction was found only for fibrinogen levels: at two months they were significantly higher in the estradiol group. In the long-term study (12 months), a significant decrease in AtIII and a significant increase in factor VIII were observed in both groups, without differences between treatments. The clinical relevance of the observed changes is doubtful, but nevertheless they should be considered in a more extensive evaluation of the potential cardiovascular risk and benefits of hormone use.

KW - Antithrombin III

KW - factor VIII

KW - thromboembolic risk

UR - http://www.scopus.com/inward/record.url?scp=0025852416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025852416&partnerID=8YFLogxK

U2 - 10.1016/0049-3848(91)90663-H

DO - 10.1016/0049-3848(91)90663-H

M3 - Article

C2 - 1649497

AN - SCOPUS:0025852416

VL - 62

SP - 1

EP - 8

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 1-2

ER -